News
New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback